5. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010; 376(9735):124–136.
7. Jee D, Lee WK, Kang S. Prevalence and risk factors for diabetic retinopathy: the Korea National Health and Nutrition Examination Survey 2008–2011. Invest Ophthalmol Vis Sci. 2013; 54(10):6827–6833.
9. Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg P. Productivity and medical costs of diabetes in a large employer population. Diabetes Care. 2002; 25(1):23–29.
10. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012; 29(7):855–862.
13. Wallick CJ, Hansen RN, Campbell J, Kiss S, Kowalski JW, Sullivan SD. Comorbidity and health care resource use among commercially insured non-elderly patients with diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina. 2015; 46(7):744–751.
14. Chen X, Modjtahedi BS, Young LH. Management of diabetic macular edema: is it time to say goodbye to macular laser? Int Ophthalmol Clin. 2015; 55(4):113–122.
15. Cheung N, Wong IY, Wong TY. Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications. Diabetes Care. 2014; 37(4):900–905.
16. Jiang S, Barner JC, Park C, Ling YL. Treatment patterns of anti-vascular endothelial growth factor and laser therapy among patients with diabetic macular edema. J Manag Care Spec Pharm. 2015; 21(9):735–741.
17. Jusufbegovic D, Mugavin MO, Schaal S. Evolution of controlling diabetic retinopathy: changing trends in the management of diabetic macular edema at a single institution over the past decade. Retina. 2015; 35(5):929–934.
19. Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL 3rd, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012; 119(11):2312–2318.
21. Elman MJ, Ayala A, Bressler NM, Browning D, Flaxel CJ, Glassman AR, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015; 122(2):375–381.
22. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012; 119(4):789–801.
23. Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012; 119(8):1658–1665.
24. Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014; 121(11):2247–2254.
25. Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014; 121(12):2473–2481.
26. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014; 121(10):1904–1914.
27. Nozaki M, Suzuma K, Inoue M, Kawasaki R, Kida T, Takamura Y, et al. Preference and trends of treatment for diabetic retinopathy in Korea and Japan. Nippon Ganka Gakkai Zasshi. 2013; 117(9):735–742.
28. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing Snellen visual acuity measurements. Retina. 2010; 30(7):1046–1050.
29. Bressler SB, Edwards AR, Andreoli CM, Edwards PA, Glassman AR, Jaffe GJ, et al. Reproducibility of Optovue RTVue optical coherence tomography retinal thickness measurements and conversion to equivalent Zeiss Stratus metrics in diabetic macular edema. Transl Vis Sci Technol. 2015; 4(1):5.
![crossref](/image/icon/bnr_ref_cross.gif)
31. Campbell J, Cole AL, Almony A, Ingraham H, Holekamp NM, Marks S, et al. Real world vision outcomes in DME treated with anti-VEGF injections - An analysis of EMR data from a large health system. Invest Ophthalmol Vis Sci. 2014; 55(13):3065.
32. Patrao NV, Antao S, Egan C, Omar A, Hamilton R, Hykin PG, et al. Real-world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom National Health Service setting. Am J Ophthalmol. 2016; 172:51–57.
33. Dugel PU, Layton A, Varma RB. Diabetic macular edema diagnosis and treatment in the real world: an analysis of Medicare claims data (2008 to 2010). Ophthalmic Surg Lasers Imaging Retina. 2016; 47(3):258–267.
![crossref](/image/icon/bnr_ref_cross.gif)
34. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010; 33(11):2399–2405.
35. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118(4):615–625.
38. Sharareh B, Gallemore R, Taban M, Onishi S, Wallsh J. Recalcitrant macular edema after intravitreal bevacizumab is responsive to an intravitreal dexamethasone implant in retinal vein occlusion. Retina. 2013; 33(6):1227–1231.
39. Busch C, Zur D, Fraser-Bell S, Laíns I, Santos AR, Lupidi M, et al. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol. 2018; 55(8):789–796.
42. Kim K, Kim ES, Kwak HW, Yu SY. Long-term outcomes of diabetic macular edema following initial intravitreal ranibizumab injection based on morphologic pattern. J Korean Ophthalmol Soc. 2016; 57(10):1604–1612.
![crossref](/image/icon/bnr_ref_cross.gif)
43. Moon BG, Lee JY, Yu HG, Song JH, Park YH, Kim HW, et al. Efficacy and safety of a dexamethasone implant in patients with diabetic macular edema at tertiary centers in Korea. J Ophthalmol. 2016; 2016:9810270.
![crossref](/image/icon/bnr_ref_cross.gif)